GSK– tag –
-
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
AI Firm Noetik Achieves First Milestone in GSK Collaboration, Deploying OCTO-VC Foundational Model’s Inference and Fine-tuning Capabilities for Oncology Drug Discovery
Business Wire Global Overview AI company Noetik has successfully achieved its first short-term milestone in a five-year strategic collaboration and licensing agreement with GSK. This accomplishment was met by Noetik's delivery and deploy... -
Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data
The Bio Report USA Overview A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis's beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis's siRNA therapy, D... -
GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation
GSK USA Overview GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA.... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr...
1